Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/11087
Effects of HCV Eradication on Bone mineral density in HIV/HCV Coinfected Patients
Carrero, Ana | Berenguer, Juan | Hontañón, Víctor | Guardiola, Josep M | Navarro, Jordi | von Wichmann, Miguel A | Téllez, María Jesús | Quereda, Carmen | Santos, Ignacio | Sanz, José | Galindo, María J | Hernández-Quero, José | Jimenez-Sousa, Maria Angeles ISCIII | Pérez-Latorre, Leire | Bellón, José M | Resino, Salvador ISCIII | Esteban, Herminia | Martínez, Esteban | González-García, Juan
Clin Infect Dis. 2020 Sep 15;ciaa1396.
Little is known about the effects of eradication of HCV on bone mineral density (BMD) and biomarkers of bone remodeling in HIV/HCV coinfected patients. We prospectively assessed standardized BMD (sBMD) at the lumbar spine and femoral neck, World Health Organization (WHO) BMD categories at both sites, and plasma concentrations of soluble receptor activator of nuclear factor-kappaβ ligand (sRANKL), and osteoprotegerin (OPG) at baseline (the date of initiation of anti-HCV therapy) and at 96 weeks. A total of 238 patients were included, median age 49.5 years, 76.5% males, 48.3% with cirrhosis, 98.3% on antiretroviral therapy, median CD4+ cell count 527 cells/mm 3, 86.6% with HIV-1 RNA < 50 copies/mL. The prevalence of osteoporosis at baseline at the lumbar spine (LS) and femoral neck (FN) was 17.6% and 7.2%, respectively. Anti-HCV therapy comprised pegylated interferon and ribavirin (PegIFN-RBV) plus one direct-acting antiviral in 53.4%, PegIFN-RBV in 34.5%, and sofosbuvir/RBV in 12.2%. A total of 145 (60.9%) patients achieved sustained viral response (SVR). No significant effect of SVR was observed on sBMD for the interaction between time and SVR either in the LS (P=0.801) or the FN (P=0.911). Likewise, no significant effect of SVR was observed in plasma levels of sRANKL (P=0.205), OPG (P=0.249), and sRANKL/OPG ratio (P=0.123) for the interaction between time and SVR. No significant correlation was found between fibrosis by transient elastography, and LS and FN sBMD, at baseline, and week 96. SVR was not associated with significant changes in BMD nor biomarkers of bone remodeling in HIV/HCV-coinfected persons.
Antiviral Agents | Biomarkers | Bone | Coinfection | HIV | Hepatitis C | Osteoporosis
Files in this item